Biora Therapeutics Advances BioJet™ Oral Delivery Platform for Needle-Free Drug Delivery at PODD Conference
Biora Therapeutics, Inc. (Nasdaq: BIOR), a biotech company focused on transforming drug delivery, presented new advancements for its BioJet™ Oral Delivery Platform at the 14th Annual Partnership in Drug Delivery (PODD) meeting in Boston, Massachusetts. The BioJet technology is designed as a swallowable, needle-free autoinjector to replace traditional injections with oral delivery, aiming to increase patient comfort and expand therapeutic options.
Biora shared that it has successfully miniaturized the BioJet device to a more patient-friendly 00-size capsule, which has garnered interest from both patients and pharmaceutical partners. This new version offers a significant payload capacity, enabling the delivery of doses greater than 50 milligrams—currently the largest payload for any ingestible injectable device.
In recent trials, the BioJet 00-size device achieved autonomous delivery to the small intestine in canine models. Following positive results, Biora has expanded collaborations with major pharmaceutical partners to expedite testing in advanced animal models. Full functional testing is set to conclude in Q4 2024, with molecule-specific feasibility studies scheduled for Q1 2025.
The BioJet platform has shown promise in over 30 in vivo studies, achieving over 30% oral bioavailability compared to intravenous administration for molecules such as peptides, antibodies, and antisense oligonucleotides. This efficiency is equivalent to 60–80% bioavailability compared to subcutaneous injections, marking a notable advancement in non-invasive drug delivery.
